Seven countries start trials for first ever mRNA lung cancer vaccine, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

Seven countries start trials for first ever mRNA lung ******* vaccine, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

New Delhi: BNT116, a vaccine developed by BioNTech is being tested to determine its effectiveness in targeting and eliminating ******* cells, and preventing them from coming back. This vaccine aims to treat non-small cell lung ******* (NSCLC), the most prevalent form of lung *******.

The phase 1 trial for BNT116 is underway at 34 sites across seven countries, including the ***, US, and Germany. The first *** patient received the vaccine this Tuesday. Around 130 patients, including 20 from the ***, will receive BNT116 combined with immunotherapy, targeting various stages of lung *******. Using mRNA technology similar to COVID-19 vaccines, BNT116 aims to enable the immune system to target NSCLC tumour markers, attacking ******* cells while sparing healthy ones.

Lung ******* is the top cause of ******* deaths worldwide, accounting for around 1.8 million deaths annually. Survival rates are especially low in the advanced stages of the ********, where the ******* has spread.

Janusz Racz, a 67-year-old AI scientist from London, was the first *** patient to receive the vaccine. After being diagnosed with lung ******* in May and starting chemotherapy and radiotherapy, he chose to join the trial. “As a scientist, I understand that medical progress depends on study participants,” Racz told The Guardian.

Racz received six injections, each with different RNA strands, over 30 minutes at the National Institute for Health Research UCLH Clinical Research Facility. He will continue receiving the vaccine weekly for six weeks, followed by treatments every three weeks for over a year.

“We’re entering an exciting new era with mRNA-based immunotherapy for lung *******,” University College London Hospitals NHS Foundation Trust (UCLH), Professor Siow Ming told The Guardian.

Prof Siow Ming Lee, a consultant medical oncologist at the University College London Hospitals NHS foundation Trust (UCLH), which is leading the trial in the ***, said the goal is to prevent lung ******* from returning, which often happens even after surgery and radiation. “I’ve studied lung ******* for 40 years. In the 1990s, chemotherapy was doubtful. Now, we know that 20–30 per cent of stage 4 patients survive with immunotherapy. We hope this mRNA vaccine will further boost survival rates,” he said.

The trial is part of a broader *** effort to fast-track patients into innovative ******* vaccine trials through a new NHS “matchmaking” scheme. This programme helps eligible patients access potentially life-saving treatments.

• Published On Aug 24, 2024 at 09:27 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#countries #start #trials #mRNA #lung #******* #vaccine #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up